UY24434A1 - Nuevos imidazoles sustituidos con cicloalquilo - Google Patents

Nuevos imidazoles sustituidos con cicloalquilo

Info

Publication number
UY24434A1
UY24434A1 UY24434A UY24434A UY24434A1 UY 24434 A1 UY24434 A1 UY 24434A1 UY 24434 A UY24434 A UY 24434A UY 24434 A UY24434 A UY 24434A UY 24434 A1 UY24434 A1 UY 24434A1
Authority
UY
Uruguay
Prior art keywords
cycloalkyl
naphth
compounds
new imidazoles
replaced
Prior art date
Application number
UY24434A
Other languages
English (en)
Inventor
L Adams Jerry
S Garigipati Ravi
E Sorenson Margaret
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY24434A1 publication Critical patent/UY24434A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se describe un procedimiento para preparar imidazoles sustituidos con cicloalquilo de fórmula (I) (figura 1), en la cual: R1 es 4-piridilo, pirimidinilo, quinolilo, isoquinolinilo, quinazolin-4-ilo, 1-imidazolilo o 1-bencimidazolilo; R4 es fenilo, naft-1-ilo o naft-2-ilo, o un heteroarilo, R2 es un cicloalquilo, o cicloalquil-alquilo, o una de sus sales farmacéuticamente aceptables. Los compuestos son capaces de inhibir las proteínas proinflamatorias inducibles, tales como COX-2. Por tanto, dichos compuestos son útiles en el tratamiento de enfermedades inflamatorias. Ej. no limitante: 1-(4-oxociclohexil)-4-(4-fluorofenil)-5-[2-metoxi-pirimidin-4-il]imidazol
UY24434A 1996-01-11 1997-01-08 Nuevos imidazoles sustituidos con cicloalquilo UY24434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1001096P 1996-01-11 1996-01-11

Publications (1)

Publication Number Publication Date
UY24434A1 true UY24434A1 (es) 1997-06-06

Family

ID=21743297

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24434A UY24434A1 (es) 1996-01-11 1997-01-08 Nuevos imidazoles sustituidos con cicloalquilo

Country Status (24)

Country Link
US (1) US6329526B1 (es)
EP (1) EP0889726B1 (es)
JP (1) JP2000503304A (es)
CN (1) CN1213305A (es)
AP (1) AP9700912A0 (es)
AR (1) AR005434A1 (es)
AT (1) ATE276248T1 (es)
AU (1) AU715315B2 (es)
BR (1) BR9708149A (es)
CZ (1) CZ218198A3 (es)
DE (1) DE69730704T2 (es)
ES (1) ES2229335T3 (es)
HU (1) HUP9901233A2 (es)
ID (1) ID18759A (es)
IL (1) IL125224A0 (es)
MA (1) MA24055A1 (es)
MX (1) MX9805628A (es)
NO (1) NO983182L (es)
NZ (1) NZ330889A (es)
PL (1) PL327939A1 (es)
TR (1) TR199801350T2 (es)
UY (1) UY24434A1 (es)
WO (1) WO1997025048A1 (es)
ZA (1) ZA97173B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ATE247470T1 (de) * 1996-01-11 2003-09-15 Smithkline Beecham Corp Neue substituierte imidazolverbindungen
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US6096739A (en) * 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
WO1999001452A1 (en) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999017776A1 (en) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Novel cycloalkenyl substituted compounds
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
US6096899A (en) * 1998-04-14 2000-08-01 The Regents Of The University Of Michigan Cylic imidazole compounds having relatively low hydrogen content and relatively high nitrogen content and polymers formed therefrom
GB9809869D0 (en) * 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
EP1080087A4 (en) 1998-05-22 2001-11-21 Smithkline Beecham Corp NEW 2-ALKYL-SUBSTITUTED IMIDAZOLES
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1112070B1 (en) 1998-08-20 2004-05-12 Smithkline Beecham Corporation Novel substituted triazole compounds
WO2000025791A1 (en) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
TR200200673T2 (tr) * 1999-09-17 2002-12-23 Smithkline Beecham Corporation Rinovirüs enfeksiyonlarında csaıd'lerin kullanılması
JP2003514900A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
EP1233950B1 (en) 1999-11-23 2005-10-05 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
US7473695B2 (en) * 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
PT1608407E (pt) * 2003-03-20 2006-12-29 Pharmacia Corp Formulação dispersível de um agente anti-inflamatório
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US7105467B2 (en) * 2003-07-08 2006-09-12 Pharmacore, Inc. Nickel catalyzed cross-coupling reactions between organomagnesium compounds and anisole derivatives
US7105707B2 (en) * 2003-12-17 2006-09-12 Pharmacore, Inc. Process for preparing alkynyl-substituted aromatic and heterocyclic compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US20080119498A1 (en) * 2004-12-06 2008-05-22 Masatomo Kato Therapeutic Agent for Pruritus Comprising P38 Map Kinase Inhibitor as the Active Ingredient
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP2007145819A (ja) * 2005-10-28 2007-06-14 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007056016A2 (en) * 2005-11-02 2007-05-18 Kemia, Inc. Bisamide cytokine inhibitors
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
WO2015072580A1 (ja) 2013-11-14 2015-05-21 学校法人同志社 細胞増殖促進または細胞障害抑制による角膜内皮治療薬
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar Hyaluronic acid conjugated with dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment or suppression of inflammatory diseases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748119A (en) 1954-06-23 1956-05-29 Searle & Co 6-furyl and 6-thienyl derivatives of 4-trifluoromethyl-2-pyrimidinamines
US3557114A (en) 1968-12-23 1971-01-19 Merck & Co Inc 1-substituted-3-(2-pyrimidinyl) imidazolium salts
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
CA1175431A (en) 1980-07-25 1984-10-02 Alfred Sallmann Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
CA2098177A1 (en) 1990-12-13 1992-06-13 Jerry L. Adams Csaids
AU9169991A (en) 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
IL104369A0 (en) * 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
IL110296A (en) 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
PT672041E (pt) 1993-10-01 2002-04-29 Novartis Ag Derivados da piridina farmacologicamente activos e processos para a sua preparacao
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
ATE325113T1 (de) 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
EP0802908A4 (en) * 1995-01-12 2001-04-11 Smithkline Beecham Corp NEW COMPOUNDS
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
EP0883402A4 (en) 1996-01-11 1999-08-11 Smithkline Beecham Corp NEW CYCLOALKYL-SUBSTITUTED IMIDAZOLES
ATE247470T1 (de) 1996-01-11 2003-09-15 Smithkline Beecham Corp Neue substituierte imidazolverbindungen
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6096739A (en) 1996-03-25 2000-08-01 Smithkline Beecham Corporation Treatment for CNS injuries
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
WO1998022109A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists

Also Published As

Publication number Publication date
DE69730704D1 (de) 2004-10-21
ES2229335T3 (es) 2005-04-16
MA24055A1 (fr) 1997-10-01
JP2000503304A (ja) 2000-03-21
ZA97173B (en) 1997-07-18
IL125224A0 (en) 1999-03-12
DE69730704T2 (de) 2005-09-22
MX9805628A (es) 1998-11-29
EP0889726A1 (en) 1999-01-13
AP9700912A0 (en) 1997-01-31
US6329526B1 (en) 2001-12-11
EP0889726A4 (en) 1999-07-21
WO1997025048A1 (en) 1997-07-17
NZ330889A (en) 2000-03-27
HUP9901233A2 (hu) 2000-04-28
AU715315B2 (en) 2000-01-20
ATE276248T1 (de) 2004-10-15
BR9708149A (pt) 1999-07-27
PL327939A1 (en) 1999-01-04
ID18759A (id) 1998-05-07
TR199801350T2 (xx) 1998-10-21
CN1213305A (zh) 1999-04-07
NO983182L (no) 1998-09-09
AR005434A1 (es) 1999-06-23
EP0889726B1 (en) 2004-09-15
CZ218198A3 (cs) 1999-09-15
AU2242597A (en) 1997-08-01

Similar Documents

Publication Publication Date Title
UY24434A1 (es) Nuevos imidazoles sustituidos con cicloalquilo
AR032279A1 (es) Metodo para inhibir una o mas actividades de quinasa proteinica, compuesto de 2 - pirazolin-5-ona inhibidor de quinasa proteinica y composicion farmaceutica que lo comprende
DE68907921D1 (de) Substituierte pyrrol-, pyrazol- und triazol-angiotensin ii-antagonisten.
DE69025473D1 (de) Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
NO176049C (no) Analogifremgangsmåte for fremstilling av terapeutiske imidazoler som blokkerer angiotensin-II-reseptorer
DE69413542T2 (de) Perhydroisoindolderivate als substanz p antagonisten
RS50209B (sr) Derivati pirazolokarboksilne kiseline, njihova priprema, farmaceutske kompozicije sa sadržajem istih
NO20015309D0 (no) 1- (P-tienylbenzyl)-imidazoler som antiotensin-(1- 7)reseptoragonister, fremgangsmåte for fremstilling og anvendelseav de samme og farmasöytiske preparater som inneholder nevnteforbindelser
DE60231608D1 (de) Cyclische amidinderivate
DE69931409D1 (de) Therapeutische Verwendung als Histamin-H3-Rezeptor Liganden von Alkylaminen, die kein Imidazole enthalten
ATE292118T1 (de) Pyrazolderivative als p-38 map kinase inhibitoren
ID21775A (id) Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
DE60103147D1 (de) 1,1-dioxoisothiazolidin-substituierte indazole als inhibitoren der zellproliferation
UY26253A1 (es) Derivados del triazol y del imidazol
YU173791A (sh) Indol i benzimidazol-supstituisani imidazol i benzimidazol derivati
PE20081850A1 (es) Derivados ciclizados como inhibidores de la eg-5
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DK0492105T3 (da) Angiotensin-II-receptor-blokkerer til behandling af cardial hypertrofi
JO2274B1 (en) Derivatives of 1-renesulfinyl-2-aryl-pyrrolidine and piperidine
ATE246684T1 (de) Substituierte 1,4-dihydroindeno(1,2-c)pyrazole als inhibitoren von tyrosinkinase
AR035944A1 (es) Proceso para la preparacion de 4-(3-clorofenil)-6-[(4-clorofenil)hidroxi (1-metil-1h-imidazol-5-il)metil]-1-metil-2(1h)-quinolinona y sus sales farmaceuticamente aceptables
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
SE9902387D0 (sv) New pharmaceutically active compounds
EE200000585A (et) 5,6-dikloro-2-(isopropüülamino)-1-(ß-L-ribofuranosüül)-1H-bensimidasooli vorm VI